Savanna® - First experiences from the use of a true molecular Point-of-Care test system for decentralized testing in hospital emergency wards
QuidelOrtho
Monday 13th February I 11:00 - 12:00
Online
Overview
The Webinar provides an overview of the technology of a new molecular platform (Savanna®, QuidelOrtho Corp.) specifically designed for rapid Point-of-Care testing (POCT), including current field experiences and its performance in POCT. Potential cost savings resulting from the use as rapid POC molecular test will be presented.
Learning objective:
Participants will receive a detailed overview of a true PCR POCT system and gain insights as well as review experiences of its implementation in settings where near-patient testing can lead to substantial benefit.
Company bio
QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission of developing and manufacturing innovative technologies that raise the performance of diagnostic testing and create better patient outcomes across the entire healthcare continuum. Ranked among the world’s largest in vitro diagnostics (IVD) providers with more than 120 years of collective experience, we combine industry-leading expertise in immunoassay and molecular testing with a global footprint in clinical labs and transfusion medicine. Our company’s comprehensive product portfolio delivers accuracy, speed, automation and access, providing critical information when and where it is needed most. Inspired by a spirit of service, the QuidelOrtho family is committed to enhancing the wellbeing of people worldwide and happy in the knowledge we are making a difference.
Presenter
Dr. Jürgen Becker
Scientific Marketing Manager EMEA, QuidelOrtho
For over 5 years Dr. Jürgen Becker has been the Scientific Marketing Manager at QuidelOrtho, a manufacturer of in vitro diagnostics for the central laboratory and for point-of-care testing. Before that, he worked for 18 years for various pharmaceutical and diagnostic companies in medical scientific and regulatory departments concerning clinical research and as a qualified person. His areas of focus include infectious diseases, in which he regularly conducts and publishes clinical studies. His most famous publication is a feasibility study on molecular MRSA screening in nursing homes for elderly (Becker & Diel; J Occup Med Toxicol 2017 Feb 3;12:3).
